JFS Wealth Advisors’s Amicus Therapeutics FOLD Stock Holding History

JFS Wealth Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-282	Closed	-$2.66K	–	1957
2024 Q4	$2.66K	Hold	282	–	–	﹤0.01%	1364
2024 Q3	$3.01K	Hold	282	–	–	﹤0.01%	1316
2024 Q2	$2.8K	Hold	282	–	–	﹤0.01%	1304
2024 Q1	$3.32K	Buy	+282	New	+$3.61K	﹤0.01%	1256

Other funds holding FOLD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JFS Wealth Advisors's FOLD Position: Q1 2025 in Review

JFS Wealth Advisors sold out of Amicus Therapeutics (FOLD) in Q1 2025, closing a stake of 282 shares — an estimated $2.66K sold.

JFS Wealth Advisors first reported a position in FOLD in Q1 2024 and held it in 4 quarters. The position peaked at $3.32K in Q1 2024. 286 funds tracked by Wall St. Rank hold FOLD as of Q1 2025.

JFS Wealth Advisors reported no remaining Amicus Therapeutics position as of Q1 2025 after selling out during the quarter.
JFS Wealth Advisors sold 282 Amicus Therapeutics shares in Q1 2025, an estimated $2.66K.
JFS Wealth Advisors first reported a position in Amicus Therapeutics in Q1 2024 and held it in 4 quarters.
JFS Wealth Advisors's Amicus Therapeutics position peaked at $3.32K in Q1 2024.
286 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2025.

Based on JFS Wealth Advisors's 13F filing for Q1 2025, filed 22 Apr 2025.